Loading patent…
AssigneeBrown University
InventorsAlison R. Amenta, Atilgan Yilmaz, Beth A. McKechnie, Justin R. Fallon
Estimating the term…
The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.
A method of treating a muscular dystrophy in a patient in need thereof, the method comprising:
A method of treating a muscular dystrophy in a patient in need thereof, the method comprising:
A method of treating a muscular dystrophy in a patient in whom a utrophin deficiency characterized by a decreased level of utrophin protein or activity has been determined by measuring the level of membrane-associated utrophin at the sarcolemma in a sample of muscle cells from the patient and comparing with a reference value, comprising administering a dose of a biglycan polypeptide to the patient, wherein the biglycan polypeptide comprises an amino acid sequence corresponding to amino acids 38-365 of SEQ ID NO:
Dependencies are inferred from the claim text.